ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Unternehmens-codeNDRA
Name des UnternehmensENDRA Life Sciences Inc
IPO-datumJun 28, 2017
Gegründet am2007
CEOMr. Alexander Y. Tokman
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse3600 Green Ct Ste 350
StadtANN ARBOR
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl48105-2440
Telefon17343350468
Websitehttps://www.endrainc.com/
Unternehmens-codeNDRA
IPO-datumJun 28, 2017
Gegründet am2007
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten